Evogene Reports Wider Q1 2026 Loss as AI-Driven Small-Molecule Strategy Takes Center Stage
Evogene Reports Wider Q1 2026 Loss as AI-Driven Small-Molecule Strategy Takes Center Stage
Evogene Ltd. reported a weaker financial performance for the first quarter of 2026, while emphasizing its long-term shift toward computational chemistry, generative AI, and small-molecule discovery for pharmaceutical and agricultural markets.
The company said first-quarter revenue fell to approximately $0.3 million, compared with about $2.3 million in the same period of 2025. The sharp decline was mainly linked to lower revenue from Casterra, which had recorded significant seed sales in the prior-year quarter. Evogene’s net loss widened to approximately $5.9 million, compared with roughly $3.0 million a year earlier.
Revenue Drops as Prior-Year Seed Sales Create Tough Comparison
Evogene’s first-quarter revenue decline was largely caused by the absence of major Casterra seed sales that supported results in Q1 2025. In that earlier period, Casterra generated about $2.0 million in seed-related revenue, creating a high comparison base for the latest quarter.
Cost of revenue also decreased, falling to about $0.1 million from approximately $1.5 million a year earlier. This reduction was in line with the lower revenue level and showed that the company’s direct costs moved down as sales activity slowed.
Operating Loss Remains Under Pressure
Evogene reported an operating loss of around $3.2 million for Q1 2026, compared with an operating loss of about $3.0 million in Q1 2025. Although revenue fell sharply, the company managed to reduce some operating expenses, partly balancing the impact.
Research and development expenses, net of non-refundable grants, decreased to approximately $1.8 million, compared with around $2.5 million in the same quarter last year. The company attributed the drop mainly to lower R&D spending at Biomica, Casterra, and AgPlenus.
Financing Expenses Drive Wider Net Loss
A major reason for the wider net loss was a swing in financing results. Evogene recorded net financing expenses of about $2.7 million in Q1 2026, compared with net financing income of about $1.1 million in the prior-year quarter. The change was tied mainly to accounting treatment for warrants and pre-funded warrants connected to fundraising transactions.
In February 2026, Evogene entered a warrant inducement agreement with an existing investor. The immediate exercise of warrants generated gross proceeds of approximately $3.4 million before fees and expenses. As part of the deal, the investor received new Series A-1 and Series B-1 warrants exercisable at $1.25 per share.
Cash Position and Liquidity
As of March 31, 2026, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $13.1 million. The company said consolidated cash usage during the first quarter was around $2.8 million.
This cash position is important because Evogene is still investing in technology platforms, product development, and strategic collaborations. Like many early-stage biotechnology and ag-tech platform companies, Evogene’s near-term financial results remain shaped by research spending, partnership timing, and the pace of commercialization.
Strategic Focus Shifts Toward ChemPass AI
Evogene continues to position itself as a computational chemistry company focused on the generative design of small molecules. Its core technology is ChemPass AI, a proprietary generative AI platform designed to explore chemical space and create small molecules optimized across several key parameters.
The company is applying this technology in two major markets: drug development and agricultural chemicals. In pharmaceuticals, the goal is to support the discovery of novel drug candidates. In agriculture, the platform is being used to develop next-generation products such as fungicides and other crop-protection solutions.
Lavie Bio Discontinued Operations and ICL Transaction
Evogene also reported developments related to Lavie Bio. Operations at Lavie Bio were discontinued at the end of Q1 2026, following the earlier sale of most of Lavie Bio’s assets, along with Evogene’s MicroBoost AI for Ag, to ICL in July 2025.
During the first quarter, Lavie Bio received court approval to distribute a $4.25 million dividend to shareholders. Evogene expects to receive approximately $2.9 million from that distribution, with completion expected in the second quarter of 2026.
Management Call and Investor Update
Evogene’s management hosted its Q1 2026 financial results call on May 20, 2026, at 9:00 a.m. Eastern Time and 16:00 Israel time. The company listed the event under its investor relations webcast section.
The earnings call highlighted the company’s transition from a broader life-science platform structure toward a more focused AI-powered small-molecule discovery model. This transition may reduce some operational complexity over time, but it also places greater importance on partnerships, validation, and future commercial milestones.
Outlook: High Potential, But Execution Remains Key
Evogene’s Q1 2026 results show a company in transition. The financial numbers were weak, especially because of lower revenue and higher financing expenses. However, management continues to emphasize the long-term value of its AI technology and its ability to support product discovery in pharma and agriculture.
For investors, the key questions are clear: Can Evogene turn ChemPass AI into meaningful partnerships? Can its internal pipeline create valuable candidates? And can the company manage cash carefully while moving toward stronger commercial results?
Overall, Evogene’s first quarter was financially challenging, but strategically important. The company is betting that generative AI, computational chemistry, and focused partnerships can create long-term value despite near-term losses and uneven revenue.
#Evogene #EVGN #Earnings #ArtificialIntelligence #SlimScan #GrowthStocks #CANSLIM